References
- Kamitsuji H, Whitworth J A., Kincaid-Smith P. Effects of heparin and defibrinotide on malignant hypertension in rats. Clin & Exper Hyper-Theory & Practice 1986; 8(6)1009–1032
- Susic D, Mandal A K., Kentera D. Heparin lowers the blood pressure in hypertensive rats. Hypertension 1982; 4(5)681–685
- Wilson S K., Solez K, Boitnott J K., Heptinstall R H. The effects of heparin treatment on hypertension and vascular lesions in stroke-prone spontaneously hypertensive rats. American J Pathol 1981; 102: 62–71
- Purkerson M L., Joist J H., Greenberg D, Kay D, Hoffsten P E., Kluhr S. Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats. Thromb Res 1982; 26: 227–240
- Guyton J R., Rosenberg R, Clowes A W., Karnovsky M J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. I. In vitro studies with anticoagulant and non-anticoagulant heparin. Circ Res 1980; 46: 628–633
- Clowes A W., Karnovsky M J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625–626
- Hoover R L., Rosenberg R, Hearing W, Karnovsky M J. Inhibition of rat arterial smooth muscle cell proliferation by heparin.II. In vitro studies. Circ Res 1980; 47: 578
- Hiebert L M., Jaques L B. The observation of heparin on endothelium after injection. Thromb Res 1976; 8: 195–204
- Schlatmarnn R S.A.F.M., Jamsen A P., Prenan H, Van der Korst J K., Majoor C LH. The natriuretic and aldosterone suppressive action of heparin and some related polysaccharides. J Clin Endocrinol Metab 1964; 24: 35–47
- Johnston C I., Mendelsohn F, Casley D. Plasma renin determination employing a radioimmunoassay for angiotensin I. Proc Aust Soc Med Res 1969; 2: 271–272
- Ryan G R., Coghlan J P., Scoggins B A. The granulated peripolar epithelial cell: a potential secretory component of the renal juxtaglomerular complex. Nature 1979; 277: 655–656
- Seyle H, Hall C E., Rowlley E M. Malignant hypertension produced by treatment with deoxycorticosterone acetate and sodium chloride. Can Med Assoc J 1943; 49: 88–92
- Gavras H, Brunner H R., Laragh J H., Vaughan E D., Koss M, Cote L J., Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. Circ Res 1975; 36: 300–309
- Holmer E, Karachi K, Soderstrom G. The molecular weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395–40
- Laurent T C., Tengblau A, Thunberg L, Hook M, Lindahl U. The molecular weight dependence of the anticoagulant activity of heparin. Biochem J 1978; 175: 691–701
- Andersson L O., Barrowcliffe T W., Holmer E, Johnson E. A., Soderstrom G. Molecular weight dependence of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531–541
- Berguvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381–391
- Niada R, Mantovani M, Primo G, Pescador R, Berti F, Omini C, Falco G C. Antithrombotic activity of a polydeoxyribonucleotidic substance extracted from mammalian organs: a possible link with prostacyclin. Thromb Res 1981; 23: 233–246
- Niada R, Mantovani M, Primo G, Pescador R, Porta R. PGI2-generation and antithrombotic activity of orally administered defibrotide. Pharmacol Res Comm 1982; 14: 949–957
- Pescador R, Mantovani M, Primo G, Madonna M. Pharmokinetics of defibrotide and of its profibrinolytic activity in the rabbit. Thromb Res 1983; 30: 1–11
- Olson J L. Role of heparin as a protective agent following reduction of renal mass. Kidney Int 1984; 25: 376–382